BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35902275)

  • 1. Analysis of actionable genetic alterations in lung carcinoma from the VA National Precision Oncology Program.
    Jalal SI; Guo A; Ahmed S; Kelley MJ
    Semin Oncol; 2022 Jul; ():. PubMed ID: 35902275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program.
    Vashistha V; Armstrong J; Winski D; Poonnen PJ; Hintze B; Price M; Snowdon JL; Weeraratne D; Brotman D; Jackson GP; Kelley MJ
    JCO Oncol Pract; 2021 Jul; 17(7):e1012-e1020. PubMed ID: 33780286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ; Haslam A; Gill J; Prasad V
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.
    Kuang X; Xiao J; Dai LX; Zhang LH; He BX
    Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The landscape of actionable genomic alterations in lung adenocarcinomas in India.
    Sharma R; Kamireddy AP; Hussaini SM; Chatterjee S; Hasan Q; Jain J
    Front Genet; 2023; 14():1256756. PubMed ID: 38155717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variation in targetable genomic alterations in non-small cell lung cancer by genetic ancestry, sex, smoking history, and histology.
    Adib E; Nassar AH; Abou Alaiwi S; Groha S; Akl EW; Sholl LM; Michael KS; Awad MM; JÓ“nne PA; Gusev A; Kwiatkowski DJ
    Genome Med; 2022 Apr; 14(1):39. PubMed ID: 35428358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland.
    Grosse A; Grosse C; Rechsteiner M; Soltermann A
    Diagn Pathol; 2019 Feb; 14(1):18. PubMed ID: 30744664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Landscape of NSCLC in the Republic of Ireland.
    Keogh RJ; Barr MP; Keogh A; McMahon D; O'Brien C; Finn SP; Naidoo J
    JTO Clin Res Rep; 2024 Feb; 5(2):100627. PubMed ID: 38333230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    Tan AC; Tan DSW
    J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
    Mack PC; Klein MI; Ayers KL; Zhou X; Guin S; Fink M; Rossi M; Ai-Kateb H; O'Connell T; Hantash FM; Oh WK; Newman S; Schadt EE; Chen R; Hirsch FR
    Oncologist; 2022 Jun; 27(6):476-486. PubMed ID: 35298662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
    Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
    Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than
    Seegobin K; Majeed U; Wiest N; Manochakian R; Lou Y; Zhao Y
    Front Oncol; 2021; 11():750657. PubMed ID: 34926258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying a wide range of actionable variants using capture-based ultra-deep targeted sequencing in treatment-naive patients with primary lung adenocarcinoma.
    Chen L; Chen M; Lin J; Chen X; Yu X; Chen Z; Jin L
    Int J Clin Exp Pathol; 2020; 13(3):525-535. PubMed ID: 32269691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer.
    Stein MK; Oluoha O; Patel K; VanderWalde A
    J Pers Med; 2021 Jun; 11(6):. PubMed ID: 34198738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.